Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Axes 126 Companies from Biotech Index; Cut Includes Genomics Cos.

NEW YORK, Jan 22 – The Nasdaq said Monday it had slashed the number of companies it would include in its biotechnology index from 202 to 76, including a number of genomics companies that recently raised tens of millions of dollars last year but have since seen their share prices fall.

The change in the index will be effective Tuesday.

Among the genomics companies that will no longer be included in the index are Compugen, DeCode, Gemini Genomics, Informax, Hyseq, Large Scale Biology, Lynx Therapeutics, Rosetta Inpharmatics, and Variagenics.

Most of these companies are now trading at or near their 52-week lows, as the result of a downturn in the market.

In a statement, the Nasdaq said that securities in the index must meet minimum requirements for price, market value, and average daily share volume.

The Nasdaq Biotechnology Index, which was started in 1993, increased 23 percent in 2000.  

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.